Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 19/20 | 0.80 |
| ▸ | HEXB | P07686 | 3/20 | 0.80 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539781 | 1.00 | OGA (0.80) | OGAHEXBHOGA1 | |
| SCHEMBL4570007 | 1.00 | OGA (0.80) | OGAHEXBHOGA1 | |
| SCHEMBL4570006 | 1.00 | OGA (0.80) | OGAHEXBHOGA1 | |
| SCHEMBL15528479 | 0.89 | OGA (0.72) | OGAHEXBHOGA1 | |
| SCHEMBL9955377 | 0.89 | OGA (1.00) | OGAHEXBHOGA1 | |
| SCHEMBL4538597 | 0.87 | OGA (0.79) | OGAHEXBHOGA1 | |
| SCHEMBL5020485 | 0.87 | OGA (0.74) | OGAHEXBHOGA1 | |
| SCHEMBL4538034 | 0.85 | OGA (0.75) | OGAHEXBHOGA1 | |
| SCHEMBL18072100 | 0.85 | OGA (0.58) | OGAHEXBHOGA1 | |
| SCHEMBL15859608 | 0.84 | OGA (0.66) | OGAHEXBHOGA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637503-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2016-09-14 | — | — | EP | claimed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | claimed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | claimed |
| WO-2012062157-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES THEREOF AS SELECTIVE GLYCOSIDASE INHIBITORS | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | claimed |
| EP-2637503-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| EP-2637503-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901087-B2 | Selective glycosidase inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2013-11-07 | — | — | US | disclosed |
| WO-2012062157-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES THEREOF AS SELECTIVE GLYCOSIDASE INHIBITORS | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062157-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES THEREOF AS SELECTIVE GLYCOSIDASE INHIBITORS | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064680-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296301-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ENGASE, OGA, GALE | OGA 2/4885HEXB 40/4885HOGA1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.